Search
Entinostat
go.drugbank.com/drugs/DB11841InvestigationalEntinostat has been investigated for the treatment of Non-Small Lung Cancer, Epigenetic Therapy. … Entinostat is under investigation for the treatment and other of Volunteers, Breast Cancer, Human Volunteers, and Normal Volunteers.
IPH 2101
go.drugbank.com/drugs/DB06049InvestigationalIPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.
Clorazepic acid
go.drugbank.com/drugs/DB00628ApprovedIllicitIn September 2020, a black box warning describing these risks was included on the product label of benzodiazepines as per FDA regulation. … Similar to other benzodiazepines, the active metabolite of clorazepate enhances the binding of gamma-aminobutyric acid (GABA) to the GABA type A (GABA-A) receptor, which promotes channel opening and neuronal
Edrophonium
go.drugbank.com/drugs/DB01010ApprovedA rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.
Categories: Compounds used in a research, industrial, or household settingTPI-ASM8
go.drugbank.com/drugs/DB05572InvestigationalTPI-ASM8 was under investigation in clinical trials NCT00822861, NCT01158898, NCT00402948, and NCT00550797, all for the treatment of Asthma.
SLx-4090
go.drugbank.com/drugs/DB05678InvestigationalSLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes. [A33218]
NV1020
go.drugbank.com/drugs/DB04969InvestigationalNV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.
E-2012
go.drugbank.com/drugs/DB05171ExperimentalE-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.
DTx-1252
go.drugbank.com/drugs/DB18086ExperimentalDTx-1252 is a siRNA therapeutic under investigation for the treatment of Charcot-Marie-Tooth Disease type 1A (CMTD1A).[L48096]
CSIC002
go.drugbank.com/drugs/DB18584ExperimentalCSIC002 is a small-molecule Sema-3A inhibitor. It is being investigated for the treatment of anterior ischemic optic neuropathy.